- Home
- FMBH vs GHRS Comparison
FMBH vs GHRS Comparison
Compare FMBH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMBH | GHRS |
|---|---|---|
| Founded | 1865 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 892.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FMBH | GHRS |
|---|---|---|
| Price | $41.81 | $13.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.20 | $30.11 |
| AVG Volume (30 Days) | 70.8K | ★ 237.1K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 12.54 | N/A |
| EPS | ★ 3.65 | N/A |
| Revenue | ★ $335,099,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.36 | N/A |
| P/E Ratio | $11.51 | ★ N/A |
| Revenue Growth | ★ 5.91 | N/A |
| 52 Week Low | $27.58 | $6.72 |
| 52 Week High | $42.50 | $20.50 |
Technical Indicators
Market Signals| Indicator | FMBH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 75.05 | 41.50 |
| Support Level | $39.70 | $13.94 |
| Resistance Level | $40.74 | $15.00 |
| Average True Range (ATR) | 0.85 | 0.84 |
| MACD | 0.37 | -0.15 |
| Stochastic Oscillator | 91.16 | 3.99 |
Price Performance
Historical ComparisonAbout FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.